466 related articles for article (PubMed ID: 16715122)
41. Inhibitory H3 receptors on sympathetic nerves of the pithed rat: activation by endogenous histamine and operation in spontaneously hypertensive rats.
Godlewski G; Malinowska B; Buczko W; Schlicker E
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):261-6. PubMed ID: 9050021
[TBL] [Abstract][Full Text] [Related]
42. In vitro characterization of potency, affinity and selectivity of H3-antagonists: from thioperamide to thioperamide unrelated imidazole derivatives.
Barocelli E; Ballabeni V; Caretta A; Bertoni S; Bordi F; Rivara S; Silva C; Mor M; Impicciatore M
Farmaco; 1997; 52(6-7):463-9. PubMed ID: 9372599
[TBL] [Abstract][Full Text] [Related]
43. [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain.
Jarvis MF; Schulz R; Hutchison AJ; Do UH; Sills MA; Williams M
J Pharmacol Exp Ther; 1989 Dec; 251(3):888-93. PubMed ID: 2600819
[TBL] [Abstract][Full Text] [Related]
44. Novel histamine H(3)-receptor antagonists and partial agonists with a non-aminergic structure.
Nickel T; Bauer U; Schlicker E; Kathmann M; Göthert M; Sasse A; Stark H; Schunack W
Br J Pharmacol; 2001 Apr; 132(8):1665-72. PubMed ID: 11309237
[TBL] [Abstract][Full Text] [Related]
45. [125I]iodoproxyfan and related compounds: a reversible radioligand and novel classes of antagonists with high affinity and selectivity for the histamine H3 receptor.
Stark H; Purand K; Hüls A; Ligneau X; Garbarg M; Schwartz JC; Schunack W
J Med Chem; 1996 Mar; 39(6):1220-6. PubMed ID: 8632428
[TBL] [Abstract][Full Text] [Related]
46. [125I]iodoproxyfan, a new antagonist to label and visualize cerebral histamine H3 receptors.
Ligneau X; Garbarg M; Vizuete ML; Diaz J; Purand K; Stark H; Schunack W; Schwartz JC
J Pharmacol Exp Ther; 1994 Oct; 271(1):452-9. PubMed ID: 7965746
[TBL] [Abstract][Full Text] [Related]
47. Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.
Lim HD; van Rijn RM; Ling P; Bakker RA; Thurmond RL; Leurs R
J Pharmacol Exp Ther; 2005 Sep; 314(3):1310-21. PubMed ID: 15947036
[TBL] [Abstract][Full Text] [Related]
48. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor.
Ito S; Yoshimoto R; Miyamoto Y; Mitobe Y; Nakamura T; Ishihara A; MacNeil DJ; Kanatani A; Tokita S
Eur J Pharmacol; 2006 Jan; 529(1-3):40-6. PubMed ID: 16316645
[TBL] [Abstract][Full Text] [Related]
49. Pharmacological characterization of the new histamine H4 receptor agonist VUF 8430.
Lim HD; Adami M; Guaita E; Werfel T; Smits RA; de Esch IJ; Bakker RA; Gutzmer R; Coruzzi G; Leurs R
Br J Pharmacol; 2009 May; 157(1):34-43. PubMed ID: 19413569
[TBL] [Abstract][Full Text] [Related]
50. Molecular cloning and characterization of a new human histamine receptor, HH4R.
Nakamura T; Itadani H; Hidaka Y; Ohta M; Tanaka K
Biochem Biophys Res Commun; 2000 Dec; 279(2):615-20. PubMed ID: 11118334
[TBL] [Abstract][Full Text] [Related]
51. Dibasic non-imidazole histamine H3 receptor antagonists with a rigid biphenyl scaffold.
Morini G; Comini M; Rivara M; Rivara S; Lorenzi S; Bordi F; Mor M; Flammini L; Bertoni S; Ballabeni V; Barocelli E; Plazzi PV
Bioorg Med Chem Lett; 2006 Aug; 16(15):4063-7. PubMed ID: 16713264
[TBL] [Abstract][Full Text] [Related]
52. Pharmacological activity of VUF 9153, an isothiourea histamine H3 receptor antagonist.
Barnes JC; Brown JD; Clarke NP; Clapham J; Evans DJ; O'Shaughnessy CT
Eur J Pharmacol; 1993 Nov; 250(1):147-52. PubMed ID: 8119312
[TBL] [Abstract][Full Text] [Related]
53. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
[TBL] [Abstract][Full Text] [Related]
54. Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
Medhurst AD; Briggs MA; Bruton G; Calver AR; Chessell I; Crook B; Davis JB; Davis RP; Foley AG; Heslop T; Hirst WD; Medhurst SJ; Ociepka S; Ray A; Regan CM; Sargent B; Schogger J; Stean TO; Trail BK; Upton N; White T; Orlek B; Wilson DM
Biochem Pharmacol; 2007 Apr; 73(8):1182-94. PubMed ID: 17276409
[TBL] [Abstract][Full Text] [Related]
55. Novel histamine H3 receptor antagonists: affinities in an H3 receptor binding assay and potencies in two functional H3 receptor models.
Schlicker E; Kathmann M; Reidemeister S; Stark H; Schunack W
Br J Pharmacol; 1994 Aug; 112(4):1043-8. PubMed ID: 7952862
[TBL] [Abstract][Full Text] [Related]
56. Novel nonimidazole histamine H3 receptor antagonists: 1-(4-(phenoxymethyl)benzyl)piperidines and related compounds.
Mikó T; Ligneau X; Pertz HH; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
J Med Chem; 2003 Apr; 46(8):1523-30. PubMed ID: 12672253
[TBL] [Abstract][Full Text] [Related]
57. Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies.
Sharif NA; Su SX; Yanni JM
J Ocul Pharmacol; 1994; 10(4):653-64. PubMed ID: 7714409
[TBL] [Abstract][Full Text] [Related]
58. Pharmacological characterisation of the histamine H3 receptor in the rat hippocampus.
Alves-Rodrigues A; Timmerman H; Willems E; Lemstra S; Zuiderveld OP; Leurs R
Brain Res; 1998 Mar; 788(1-2):179-86. PubMed ID: 9555002
[TBL] [Abstract][Full Text] [Related]
59. Potencies of antagonists chemically related to iodoproxyfan at histamine H3 receptors in mouse brain cortex and guinea-pig ileum: evidence for H3 receptor heterogeneity?
Schlicker E; Kathmann M; Bitschnau H; Marr I; Reidemeister S; Stark H; Schunack W
Naunyn Schmiedebergs Arch Pharmacol; 1996 Apr; 353(5):482-8. PubMed ID: 8740140
[TBL] [Abstract][Full Text] [Related]
60. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models.
Medhurst AD; Atkins AR; Beresford IJ; Brackenborough K; Briggs MA; Calver AR; Cilia J; Cluderay JE; Crook B; Davis JB; Davis RK; Davis RP; Dawson LA; Foley AG; Gartlon J; Gonzalez MI; Heslop T; Hirst WD; Jennings C; Jones DN; Lacroix LP; Martyn A; Ociepka S; Ray A; Regan CM; Roberts JC; Schogger J; Southam E; Stean TO; Trail BK; Upton N; Wadsworth G; Wald JA; White T; Witherington J; Woolley ML; Worby A; Wilson DM
J Pharmacol Exp Ther; 2007 Jun; 321(3):1032-45. PubMed ID: 17327487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
